文献速递膀胱癌与上尿路尿路上皮癌

变异组织学膀胱癌行膀胱切除术联合或不联合新辅助化疗的病理与生存结局

Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
PubMed 文献 · J Urol · 2020-08-12

该回顾性队列分析768例临床肌层浸润性膀胱癌(cT2-4N0M0)患者,比较纯尿路上皮癌、伴 divergent differentiation 的尿路上皮癌及变异组织学癌接受新辅助化疗后膀胱切除术与单纯膀胱切除术的病理降期和生存结局。结果显示各组织学亚组新辅助化疗后完全和部分病理降期率相似,但生存获益因组织学而异。

要点

  • 新辅助化疗后各组织学亚组完全降期率18%至30%,部分降期率37%至46%,差异无统计学意义。
  • 纯尿路上皮癌患者新辅助化疗获总生存获益(HR 0.71,95%CI 0.51-0.98,p=0.0013)。
  • 变异组织学患者新辅助化疗获癌症特异性生存获益(HR 0.55,95%CI 0.30-0.99,p=0.0495)。

核心结论

  • 变异组织学膀胱癌患者接受新辅助化疗的病理缓解率和生存获益与纯尿路上皮癌相近。
  • 伴 divergent differentiation 的尿路上皮癌患者无论是否使用新辅助化疗,生存结局均显著更差。

研究设计与样本

  • 回顾性分析2007至2017年单中心768例临床肌层浸润性膀胱癌(cT2-4N0M0)行膀胱切除术的患者。
  • 按组织学(纯尿路上皮癌410例、伴 divergent differentiation 的尿路上皮癌185例、变异组织学173例)和治疗策略分层。
  • 采用校正logistic和Cox回归模型评估病理降期、癌症特异性生存和总生存。

主要发现

  • 314例(41%)患者膀胱切除术前接受新辅助化疗。
  • 各组织学亚组新辅助化疗后完全病理降期率18%至30%(p=0.30),部分降期率37%至46%(p=0.40)。
  • 纯尿路上皮癌患者新辅助化疗获总生存获益(HR 0.71,95%CI 0.51-0.98,p=0.0013)。
  • 变异组织学患者新辅助化疗获癌症特异性生存获益(HR 0.55,95%CI 0.30-0.99,p=0.0495)。
  • 伴 divergent differentiation 的尿路上皮癌患者未从新辅助化疗中获得总生存或癌症特异性生存获益。

临床怎么用

  • 对变异组织学肌层浸润性膀胱癌可考虑新辅助化疗后膀胱切除术,因病理缓解率和癌症特异性生存获益与纯尿路上皮癌相近。
  • 对伴 divergent differentiation 的尿路上皮癌患者,新辅助化疗的生存获益不明确,需个体化决策。

局限性

  • 回顾性单中心研究,存在选择偏倚。
  • 各组织学亚组样本量有限,部分亚组分析效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although neoadjuvant chemotherapy is associated with a survival advantage in pure urothelial, muscle invasive bladder cancer, the role of neoadjuvant chemotherapy is less clear in variant histology or urothelial carcinoma with divergent differentiation. We compared chemotherapy response and survival outcomes of patients with nonpure urothelial carcinoma histology who were managed with neoadjuvant chemotherapy followed by cystectomy vs cystectomy alone. MATERIALS AND METHODS: We analyzed 768 patients with clinical muscle invasive bladder cancer (cT2-4N0M0) who were treated with cystectomy at a tertiary care center from 2007 to 2017. Patients were stratified by histology and treatment strategy. Adjusted logistic and Cox regression models were used to evaluate pathological downstaging, cancer specific survival and overall survival. RESULTS: The cohort consisted of 410 patients (53%) with pure urothelial carcinoma, 185 (24%) with urothelial carcinoma with divergent differentiation and 173 (23%) with variant histology. Overall, 314 patients (41%) received neoadjuvant chemotherapy prior to cystectomy. There were similar rates of complete (18% to 30%) and partial (37% to 46%) pathological downstaging with neoadjuvant chemotherapy across all histological subgroups (p=0.30 and p=0.40, respectively). However, while patients with pure urothelial carcinoma experienced an overall survival benefit (HR 0.71, 95% CI 0.51-0.98, p=0.0013) and those with variant histology experienced a cancer specific survival benefit (HR 0.55, 95% CI 0.30-0.99, p=0.0495) with neoadjuvant chemotherapy, patients with urothelial carcinoma with divergent differentiation did not experience overall or cancer specific survival benefits with the use of neoadjuvant chemotherapy prior to cystectomy. CONCLUSIONS: Among patients with muscle invasive bladder cancer those with nonpure urothelial carcinoma histology with variant histology achieved nearly equivalent response rates and survival benefits with the use of neoadjuvant chemotherapy as those with pure urothelial carcinoma, while patients with urothelial carcinoma with divergent differentiation experienced significantly worse survival outcomes regardless of the use of neoadjuvant chemotherapy prior to cystectomy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Hajiran A, Azizi M, Aydin AM, et al. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2020. PMID: 32783489. doi:10.1097/JU.0000000000001325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。